Safety & Monitoring
gastrointestinal effects, serious risks, contraindications, and what long-term data is still missing
Understanding the Risk Profile
No drug with this level of metabolic activity comes without trade-offs. Tirzepatide's most common adverse events are gastrointestinal -- nausea, diarrhea, and vomiting -- which affect roughly 15-25% of trial participants at higher doses. More serious but rarer risks include pancreatitis, gallbladder events, and a boxed warning about thyroid C-cell tumors based on rodent data. This unit walks through the full safety profile from clinical trials and post-marketing surveillance, covers contraindications and monitoring recommendations, and identifies the gaps in long-term evidence.
Safety Profile Matrix
Explore tirzepatide's adverse event rates by dose level, severity, and organ system.